Cargando…

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer

One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient. The definition of accurate predictive factors is therefore of paramount importance. So far the choice of adjuvant therapy has been based on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Munster, Pamela N, Norton, Larry
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138701/
https://www.ncbi.nlm.nih.gov/pubmed/11737886
http://dx.doi.org/10.1186/bcr323
_version_ 1782120477509025792
author Munster, Pamela N
Norton, Larry
author_facet Munster, Pamela N
Norton, Larry
author_sort Munster, Pamela N
collection PubMed
description One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient. The definition of accurate predictive factors is therefore of paramount importance. So far the choice of adjuvant therapy has been based on the number of affected lymph nodes and the hormone receptor status of the patient. This paper evaluates the use of other tumor-related markers as predictive factors for adjuvant therapy. These include HER2, p53 and Bcl-2, cathepsin B, p27, proliferating cell nuclear antigen (PCNA), cyclin D, Ki-67, and vascular endothelial growth factor (VEGF).
format Text
id pubmed-138701
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1387012003-02-27 Predictive factor for the response to adjuvant therapy with emphasis in breast cancer Munster, Pamela N Norton, Larry Breast Cancer Res Commentary One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient. The definition of accurate predictive factors is therefore of paramount importance. So far the choice of adjuvant therapy has been based on the number of affected lymph nodes and the hormone receptor status of the patient. This paper evaluates the use of other tumor-related markers as predictive factors for adjuvant therapy. These include HER2, p53 and Bcl-2, cathepsin B, p27, proliferating cell nuclear antigen (PCNA), cyclin D, Ki-67, and vascular endothelial growth factor (VEGF). BioMed Central 2001 2001-10-01 /pmc/articles/PMC138701/ /pubmed/11737886 http://dx.doi.org/10.1186/bcr323 Text en Copyright © 2001 2001 BioMed Central Ltd
spellingShingle Commentary
Munster, Pamela N
Norton, Larry
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title_full Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title_fullStr Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title_full_unstemmed Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title_short Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
title_sort predictive factor for the response to adjuvant therapy with emphasis in breast cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138701/
https://www.ncbi.nlm.nih.gov/pubmed/11737886
http://dx.doi.org/10.1186/bcr323
work_keys_str_mv AT munsterpamelan predictivefactorfortheresponsetoadjuvanttherapywithemphasisinbreastcancer
AT nortonlarry predictivefactorfortheresponsetoadjuvanttherapywithemphasisinbreastcancer